PR Newswire
VANCOUVER, June 13, 2017
NASDAQ, TSX: NVCN
VANCOUVER, June 13, 2017 /PRNewswire/- Neovasc Inc.
("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its
Annual General Meeting of Shareholders held on June 13, 2017 in Vancouver, B.C. (the "Meeting").
At the Meeting, the shareholders of the Company (the "Shareholders") re-elected board members Alexei
Marko, Paul Geyer, Dr. Jane Hsiao, Steven Rubin, Dr. William O'Neill, and Doug
Janzen to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed
results of the voting in respect of the election of directors are as follows:
|
Nominee
|
Votes For
|
% Votes For
|
Votes Withheld
|
% Votes Withheld
|
|
Alexei Marko
|
32,285,445
|
99.68%
|
103,617
|
0.32%
|
|
Paul Geyer
|
32,293,813
|
99.71%
|
95,248
|
0.29%
|
|
Dr. Jane Hsiao
|
31,123,483
|
96.09%
|
1,265,579
|
3.91%
|
|
Steven Rubin
|
31,696,494
|
97.86%
|
692,568
|
2.14%
|
|
Dr. William O'Neill
|
32,288,809
|
99.69%
|
100,252
|
0.31%
|
|
Doug Janzen
|
32,292,535
|
99.70%
|
96,527
|
0.30%
|
At the Meeting, the Shareholders also approved amendments to the Company's stock option plan and the unallocated options
thereunder (97.06% of votes cast in favour) and re-appointed Grant Thornton LLP, Chartered Accountants as auditors of the Company
(99.81% of votes cast in favour).
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not
currently available in the United States and has been available in Europe since 2015 and the Tiara™, for the transcatheter treatment of mitral valve disease, which is
currently under investigation in the United States, Canada and
Europe. The Company also sells a line of advanced biological tissue products that are used as
key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
